Navigation Links
Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production
Date:9/14/2009

conomic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

The issuer's shareholders and followers can expect updates on these matters shortly as the Company is adamant to get to the bottom of that topic and has instructed its barrister to vigorously pursue the matter.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-look
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
2. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
3. Drug Offers Hope Against Tough-to-Treat Hypertension
4. Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh
5. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
6. Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
7. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
8. Treating Childhood Leukemia With Fewer Side Effects
9. Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects
10. Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)
11. Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering Ones Risk of Infection During Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... in Western societies. One frequently cited reason is that ... infections than previous generations, thereby delaying maturation of the ... Academy, University of Gothenburg, monitored children until the age ... in relation to allergic disease. All of the children ... half of them on farms that produced milk.,Lower risk ...
(Date:7/8/2014)... kidney donors enjoy similar longevity and cardiovascular health as ... published in the American Journal of Transplantation . ... considering donation and the transplant professionals caring for them. ... by individuals aged 55 years and older has become ... disease, and heart disease, the removal of a kidney ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
(Date:7/8/2014)... were found to be three times higher when auditors ... no auditors present, according to a study in a ... titled, "Quantification of the Hawthorne effect in hand hygiene ... cohort study," published today on-line in the BMJ ... Jocelyn Srigley, who did the study as part of ...
(Date:7/8/2014)... University of Iowa researchers have discovered a biomarker that ... simple blood test to reliably predict that a pregnant ... 6 weeks into the pregnancy. , Preeclampsia is a ... resulting in an early delivery, creating immediate and potentially ... high blood pressure and protein in the urine, and ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... Calif., Sept. 4 Martin Schiff, M.D.,is an illustrious ... and weight loss. His career is detailed in "Who,s ... in America," "Who,s Who in,the World," "Who,s Who in ... Dr. Schiff recently retired to devote his expertise to ...
... ONGAR, Ireland,Sept. 4 Schofield Publishing, a division of ... it has acquired Health and,Safety Monitor publication from Silverdog ... the same time as the iconic,Health and Safety at ... then. It has been relied upon by blue-chip corporates,independent ...
... New Educational Program Kicks Off September,s Ovarian Cancer Awareness ... ... Today the National Ovarian Cancer,Coalition (NOCC) launched its newest educational initiative, Eva,s ... family who will be the first to pledge to empower and educate,women ...
... ULURU Inc. (Amex:,ULU) today announced that it is ... Conference at 3:15 p.m. Eastern Time on Thursday,September ... Inc. is an emerging specialty pharmaceutical company focused ... plastic surgery and,oral care products to provide patients ...
... YORK, Sept. 4 Come fall, women are always in ... and fit into their favorite,jeans that have become a little ... how women can look celeb-good in their,jeans and how they ... helping the United Way., (See video from Kellogg,s ...
... In some countries, lime juice is,thought to ward ... Against such a backdrop of misinformation and stigma, how ... tens of millions,of people?, Part of the answer ... media, says,Internews Network, an international media development nonprofit that ...
Cached Medicine News:Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:Schofield Publishing Enters the Newsletter Market 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 3Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Amgen (Nasdaq: AMGN ) today announced the ... of 1,776 advanced cancer patients with different types of ... multiple myeloma, which compared XGEVA ™ (denosumab) to ... study, which appeared today in the Journal of ...
... drugstore.com, inc. (Nasdaq: DSCM ), ... skincare, and vision products, today announced that the ... events with the financial community: (Logo: ... Telecom Conference Date: February 28, 2011Time: 3:20 p.m. ...
Cached Medicine Technology:The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8drugstore.com to Present at Upcoming Financial Conferences 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: